Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide vs Semaglutide on Energy Expenditure and Fatty Acid Oxidation in Obesity
NCT06745284Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of survodutide in obesity (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Absolute change in sleeping metabolic rate. Started Mar 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06745284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745284.